EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 7,100 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
최신 재무제표(Form-10K)에 따르면, 22nd Century Group Inc의 총 자산은 $0이며, 순손실입니다.
EXAS의 주요 재무 비율은 무엇인가요?
22nd Century Group Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Exact Sciences Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
22nd Century Group Inc 주요 수익원은 Tobacco Products이며, 최신 수익 발표에서 수익은 32,204,000입니다. 지역별로는 United States이 22nd Century Group Inc의 주요 시장이며, 수익은 32,204,000입니다.
Exact Sciences Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 22nd Century Group Inc의 순손실은 $0입니다.